Sat, Dec 20, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Diva Synergy Fund gains over 27% in 2010; Bernheim, Dreyfus anticipates further strong year for M&A (and for the Fund)

Friday, January 07, 2011
Opalesque Industry Update - Paris-based M&A investment manager, Bernheim, Dreyfus, has announced continuing strong performance for its flagship Diva Synergy Enhanced Fund through 2010. In the 12 month period, the Fund’s dollar class gained +27.35% net and the euro class +27.91%.

The strength of Diva Synergy reflects, to some extent, the growth in global mergers and acquisitions. According to Bernheim, Dreyfus’s January research letter, “the value of worldwide M&A totalled $2.4 trillion during the full year 2010, a 23% increase from comparable 2009 levels and the strongest full year period for M&A since 2008.

Looking forward, the letter anticipates “deal activity will remain solid, focused around strategic deal-making. Resurgent leveraged buyout activity is supported by favourable conditions in the credit markets.”

Bernheim, Dreyfus highlights three sectors where research predicts 2011 M&A will be particular buoyant:

IT. There were more than 70 tech/IT acquisitions – lathe and small – by the major industry leaders in 2010, compared to 33 in 2009 and 55 in 2008. The tech sector is certainly recovering from the recession and not shying away from deals.

Financial. With new government regulations on the books or being written in response to Dodd-Franks, many of the big banks will be looking to unload certain riskier business units, like those tied to derivatives and hedge funds. Other companies will be eager to jump in and enter the lucrative areas of financing and banking.

Healthcare. Big pharmaceutical companies like Eli Lilly, Pfizer and Merck, along with biotech firms and those in the health care services sectors will all be on the prowl. Increasing demand from an ageing population, health care legislation and expiring patents creates the need to buy smaller biotech firms with new drug discoveries.

(press release)

Bernheim, Dreyfus & Co

Paris-based Bernheim, Dreyfus & Co was founded in 2006 as an alternative investment firm focusing on M&A-related strategies, managing an event driven hedge fund – Diva Synergy.

Diva Synergy is managed by Amit Shabi and Lionel Melka. Lionel has 10 years’ of experience as an M&A advisor for blue chip clients in prestigious banks as Lazards, Calyon and Rothschilds. He has been involved in more than 20 major transactions totalling more than $50 billion.

Amit has long experience in asset management and in sales of OTC hedging strategies in companies like Rothschild and Man Group...Corporate website: Source
KM

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. Opalesque Exclusive: U.S. legal receivables fund launched in August[more]

    Benedicte Gravrand, Opalesque Geneva for New Managers: Investing in asset-backed receivables is a strategy that has been an integral part of the alternative investment space within the overall fixed income asset c

  5. Comment - High fees and low performance hit hedge funds[more]

    From FT.com: Disenchantment over high fees and lackluster performance may finally be turning the tide against hedge funds, fresh data suggest. Despite generally weak returns since the global financial crisis, hedge funds have enjoyed positive net inflows every year since 2010. This helped assets und